Pediatric patients were more likely to consume prescribed dose of Breeza than barium sulfate suspension.
Flavored neutral oral contrast materials and low-density barium sulfate suspension both provide similar small bowel distention, but pediatric patients were more likely to ingest the entire volume of neutral contrast, according to a study published in the journal Radiology.
Researchers from the Cincinnati Children’s Hospital Medical Center in Ohio sought to compare the use of a flavored beverage for neutral abdominal and pelvic imaging (Breeza; Beekley Medical, Bristol, Conn.) or a low-density barium sulfate suspension for bowel distention and patient acceptance.
Sixty-six children participated in this blinded study, 33 in each group. The Breeza group’s mean age was 13.5 years, barium sulfate suspension 13.9 years. The children were asked to rate taste, texture, and their perceived health state on scale of 0 to 10, with 0 being very bad and 10 very good. Ingested volume of the prescribed weight-based oral contrast material preparation was recorded. Maximum small bowel diameter was measured in all four abdominal quadrants. Mean bowel diameter as well as taste, texture, and health state scores were compared.
The results showed 28 of 33 patients (84.8 percent) in the Breeza group and 17 of 33 (51.5 percent) patient in the barium sulfate suspension group completed the preparation.
Scores:Taste: Breeza: 6.1 ± 2.5 Barium sulfate2.7 ± 2.5
Texture Breeza 7.3 ± 2.3 Barium sulfate 3.6 ± 2.9
Bowel distension Breeza 1.63 cm ± 0.24 Barium sulfate 1.69 cm ± 0.25
The researchers concluded that the neutral oral contrast materials Breeza and low-density barium sulfate suspension provide similar small bowel distention, but patients were more likely to ingest the entire prescribed volume of Breeza.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.